Chiauranib with weekly paclitaxel for tough ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and you’re age 18–70
- You have confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Your cancer is platinum-refractory or platinum-resistant, and you’ve had no more than 1 prior treatment for recurrence
- You’re well enough to do daily activities (ECOG 0–1) and have at least one measurable tumor spot
- Your blood tests, liver/kidney tests, and clotting tests are high enough to start treatment
- You cannot have used certain medicines recently, including VEGF/VEGFR inhibitors or weekly paclitaxel
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.